Mumbai, Nov. 18 -- The approval makes Biocon's pertuzumab the first biosimilar to receive European Commission marketing authorisation under the European Medicines Agency's (EMA) new tailored clinical approach. It follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on 17 September 2026.

The biosimilar is approved as a 420 mg concentrate for solution for infusion. It is indicated for use in combination with trastuzumab and chemotherapy in the neoadjuvant and adjuvant treatment of eligible adult patients with HER2-positive breast cancer. It is also approved for treating HER2-positive metastatic or locally recurrent unresectable breast cancer in combination with trastuzumab and docetaxel.

Biocon said th...